RAMP 203
Research type
Research Study
Full title
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)
IRAS ID
1007824
Contact name
Gloria Patrick
Contact email
Sponsor organisation
Verastem, Inc.
Eudract number
2022-004111-83
Clinicaltrials.gov Identifier
Research summary
Patients are being asked to take part in a clinical research study for participants who have been diagnosed with KRAS G12C-mutated non-small cell lung cancer (NSCLC). They will receive two drugs in this study, sotorasib (also known as LUMYKRAS™)which is approved by Medicines and Health Regulatory Authority (MHRA) in the UK, the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA); a medicine and for treatment adults with KRAS G12C-mutated NSCLC after at least one prior systemic body therapy and VS-6766 (also known as avutometinib) which is an investigational new drug. “Investigational new drug” means a drug that has not been approved as a marketed product (i.e available to be prescribed or sold) by the US Food and Drug Administration (FDA) or any other regulatory authority for the treatment of lung cancer.
VS-6766 (avutometinib) and sotorasib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The combination of VS-6766 (avutometinib) and sotorasib has so far been given to 10 participants. Laboratory studies suggests that VS-6766 (avutometinib) in combination with sotorasib, may work together to control the growth of the cancer cells. Since these two drugs work differently, the study is trying to see whether the combination will have further benefit to the participants with a NSCLC diagnosis.
REC name
London - Chelsea Research Ethics Committee
REC reference
23/LO/0601
Date of REC Opinion
5 Sep 2023
REC opinion
Further Information Favourable Opinion